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Past  
events
Coverage from the EANM 2013
On 19th–23rd October 2013 the annual congress of the European 
Association of Nuclear Medicine took place. This year special-
ists from all over Europe as well as guests from Asia and US visited 
Lyon, France. The event held at one of the biggest congress cent-
ers in Europe started on Saturday evening with an opening cer-
emony and welcome reception and lasted for four days. During the 
congress over 700 studies were presented, as well as over 1000 
posters, including 148 featured at poster-walk sessions.
Alfa-emitters in treating bone metastases
Nuclear medicine applications in bone metastasis is a well 
known topic regarding Beta particle emitters eg. Strontium 89. 
However, the usefulness of Alfa emitters is not well recognized. 
The presentations concentrated on Radium 223 effect on treating 
patients with disseminated cancers, mainly breast and prostate 
cancer. While the first one remains in the clinical studies phase, 
the latter has been approved by FDA. 
The ALSYMPCA study compared Radium223 vs placebo in 
921 prostate cancer patients divided in two groups (2:1). The re-
sults show the survival longer by 3,6 months in the Radium group 
and time to skeletal related event longer by 5,8 months [1].
Cardiologic Sessions
Many cardiologic sessions were held. Session focused on 
myocardial viability presented the usefulness of SPECT and PET in 
recognizing viable myocardium, thus selecting patients more likely 
to benefit from invasive therapy. The main conclusion is that PET 
remains the most sensitive and specific tool concerning viability, 
however MRI may have an advantage in a group of patients with 
subendocardial infarction [2–5].
Other sessions highlighted the development of CZT cam-
eras which allow us to significantly reduce the radiation dose 
and acquisition time, while improving the resolution of images. 
[6] Authors also presented TID (Transient Ischemic Dilation) and 
global wall thickening as independent risk factors of myocardial 
incident [7, 8].
Hematology and oncology
Most studies focused on applications of PET-CT in monitoring 
cancer. A study on 135 patients showed benefits of using PET-CT 
in radiotherapy planning in stage 1 and 2 Hodgkin Lymphoma 
patients [9].
A retrospective study of 1000 cases of lymphoma pointed 
out the need of radiation dose reduction during follow-up, espe-
cially when young patients undergo the treatment [10]. Presenta-
tions about ovarian cancer started the discussion in which the 
shortcomings of CA125 marker and CT where pointed out in context 
of PET-CT advantages [11, 12].
Summary
It is impossible to write about all of the sessions. During the 
whole congress, apart from scientific presentations, visitors could 
attend diagnostic and therapeutic equipment exhibitions. The event 
ended with highlights lecture and awards and closing ceremonies. 
The next congress will be held in October 2014 in Goeteborg, 
Sweden.
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